

# Contents

|  |             |
|--|-------------|
| <b>LIST OF CONTRIBUTORS .....</b>  | <b>xiii</b> |
| <b>PREFACE .....</b>   | <b>xv</b>   |
| <b>CHAPTER 1 Overview of Therapeutic Drug Monitoring.....</b>                                      | <b>1</b>    |
| <i>William Clarke</i>  |             |
| 1.1 Introduction.....  | 1           |
| 1.2 Principles of TDM.....   | 1           |
| 1.3 Clinical Areas in Which TDM is Routine Practice.....   | 2           |
| 1.3.1 Epilepsy.....  | 3           |
| 1.3.2 Organ Transplantation.....   | 5           |
| 1.3.3 Cardiology (Antiarrhythmic Drugs).....   | 7           |
| 1.3.4 Psychiatry.....  | 8           |
| 1.3.5 Infectious Disease.....  | 9           |
| 1.3.6 Oncology.....  | 11          |
| 1.4 Conclusions.....   | 12          |
| References.....  | 13          |
| <b>CHAPTER 2 Immunoassays and Issues With Interference<br/>in Therapeutic Drug Monitoring.....</b> | <b>17</b>   |
| <i>Amitava Dasgupta</i>  |             |
| 2.1 Introduction.....  | 17          |
| 2.2 Immunoassay Platforms Used in TDM.....   | 18          |
| 2.3 Interference of Bilirubin, Hemolysis, and Lipemia.....   | 20          |
| 2.4 Interferences in Digoxin Immunoassays.....   | 21          |
| 2.4.1 DLIS Interferences in Digoxin Immunoassays.....  | 22          |
| 2.4.2 Effect of Digibind and DigiFab on Digoxin<br>Immunoassays.....                               | 23          |
| 2.4.3 Potassium-Sparing Diuretics and Digoxin<br>Immunoassays.....                                 | 24          |
| 2.4.4 Herbal Supplements and Digoxin Immunoassays.....   | 25          |
| 2.5 Issues of Interferences With Immunoassays for<br>Immunosuppressants.....                       | 26          |
| 2.5.1 Metabolite Interferences in Cyclosporine<br>Immunoassays.....                                | 26          |

|       |   |    |
|-------|---|----|
| 2.5.2 | Metabolite Interferences in Tacrolimus Immunoassays .....                           | 27 |
| 2.5.3 | Metabolite Interferences in Sirolimus and Everolimus Immunoassays .....             | 27 |
| 2.5.4 | Metabolite Interferences in Mycophenolic Acid Immunoassays .....                    | 28 |
| 2.6   | Interferences in Immunoassays for Anticonvulsants .....                             | 29 |
| 2.6.1 | Interferences in Phenytoin Immunoassays .....                                       | 29 |
| 2.6.2 | Interferences in Carbamazepine Immunoassays .....                                   | 33 |
| 2.6.3 | Interferences in Phenobarbital and Valproic Acid Immunoassays .....                 | 35 |
| 2.6.4 | Interferences in Immunoassays for Newer Anticonvulsants .....                       | 35 |
| 2.7   | Interferences in Immunoassays for TCAs .....  | 35 |
| 2.7.1 | Interference of Phenothiazines and Their Metabolites in Immunoassays for TCAs ..... | 36 |
| 2.7.2 | Interference of Carbamazepine in Immunoassays for TCAs .....                        | 36 |
| 2.7.3 | Interference of Cyproheptadine and Quetiapine With Immunoassays for TCAs .....      | 37 |
| 2.7.4 | Interference of Miscellaneous Drugs With Immunoassays for TCAs .....                | 38 |
| 2.8   | Conclusions .....   | 38 |
|       | References .....  | 39 |

### **CHAPTER 3** Application of Chromatography Combined With Mass Spectrometry in Therapeutic Drug Monitoring..... 45 *Madhuri Manohar and Mark A. Marzinke*

|       |  |    |
|-------|--|----|
| 3.1   | Introduction .....                           | 45 |
| 3.2   | Liquid Chromatography .....                  | 48 |
| 3.3   | Mass Spectrometry .....                      | 51 |
| 3.3.1 | Ion Source .....                             | 51 |
| 3.3.2 | Mass Analyzers .....                         | 53 |
| 3.3.3 | Detectors .....                              | 55 |
| 3.4   | Preanalytical Stage .....                    | 55 |
| 3.5   | Application of LC-MS/MS Methods in TDM ..... | 56 |
| 3.5.1 | Immunosuppressants .....                     | 56 |
| 3.5.2 | Anticonvulsants .....                        | 57 |
| 3.5.3 | Antidepressants .....                        | 58 |
| 3.5.4 | Antifungal Drugs .....                       | 59 |
| 3.5.5 | Others Drug Classes .....                    | 61 |
| 3.6   | LC-MS/MS Limitations .....                   | 61 |
| 3.7   | Conclusions .....                            | 63 |
|       | References .....                             | 63 |

### **CHAPTER 4** Monitoring Free Drug Concentration: Clinical Usefulness and Analytical Challenges .....

*Amitava Dasgupta*

|     |                    |    |
|-----|--------------------|----|
| 4.1 | Introduction ..... | 71 |
|-----|--------------------|----|

|       |   |    |
|-------|---|----|
| 4.2   | Drug–Protein Binding .....  | 72 |
| 4.3   | Drugs Requiring Free Drug Monitoring .....  | 73 |
| 4.4   | Conditions in Which Monitoring Free Anticonvulsants<br>is Necessary .....                           | 75 |
| 4.4.1 | Clinical Utility of Monitoring Free Phenytoin<br>Concentrations .....                               | 76 |
| 4.4.2 | Clinical Utility of Monitoring Free Valproic Acid<br>Concentration .....                            | 78 |
| 4.4.3 | Clinical Utility of Monitoring Free Carbamazepine<br>Concentrations .....                           | 80 |
| 4.5   | Mechanisms of Elevated Free Anticonvulsant Levels<br>in Various Pathophysiological Conditions ..... | 80 |
| 4.5.1 | Mechanism of Elevated Free Anticonvulsant<br>Concentrations in Uremia .....                         | 80 |
| 4.5.2 | Mechanism of Elevated Free Anticonvulsant<br>Concentrations in Liver Diseases .....                 | 81 |
| 4.5.3 | Mechanism of Elevated Free Anticonvulsant<br>Concentrations in AIDS .....                           | 82 |
| 4.5.4 | Mechanism of Elevated Free Anticonvulsant<br>Concentrations in Pregnancy .....                      | 83 |
| 4.6   | Elevated Free Anticonvulsant Due to Drug–Drug<br>Interactions .....                                 | 83 |
| 4.6.1 | Displacement of One Anticonvulsant by Another<br>Anticonvulsant from Protein Binding Sites .....    | 83 |
| 4.6.2 | Displacement of Anticonvulsant from Protein<br>Binding Site by Various Drugs .....                  | 85 |
| 4.7   | Free Drug Monitoring of Drugs Bound to AGP .....  | 86 |
| 4.8   | Monitoring Free Concentrations of Immunosuppressants .....  | 87 |
| 4.8.1 | Monitoring Free Mycophenolic Acid .....   | 87 |
| 4.9   | Special Situation: Monitoring Free Digoxin .....  | 90 |
| 4.10  | Monitoring Free Concentrations of Protease Inhibitors .....   | 91 |
| 4.11  | Saliva and Tears for Determination of Free Drug<br>Concentration .....                              | 92 |
| 4.12  | Methods for Monitoring Free Drug Concentration .....  | 92 |
| 4.13  | Conclusions .....   | 94 |
|       | References .....  | 94 |

## **CHAPTER 5** Therapeutic Drug Monitoring of Newer Antiepileptic Drugs..... 101

*Gwendolyn A. McMillin and Matthew D. Krasowski*

|       |   |     |
|-------|---|-----|
| 5.1   | Introduction.....   | 101 |
| 5.2   | Therapeutic Drug Monitoring of Antiepileptic Drugs .....                            | 104 |
| 5.2.1 | Therapeutic Ranges and Specimen Types for<br>TDM of Newer Antiepileptic Drugs ..... | 104 |
| 5.2.2 | Analytical Methods Used in TDM of Antiepileptic<br>Drugs.....                       | 108 |
| 5.2.3 | Monitoring of Free Drug Fractions .....   | 110 |
| 5.2.4 | Monitoring for Special Populations .....  | 110 |
| 5.2.5 | Pharmacogenetics of Antiepileptic Drugs .....                                       | 111 |

|                  |  |            |
|------------------|--|------------|
| 5.3              | Newer Generation of Antiepileptic Drugs .....  | 112        |
| 5.3.1            | Clobazam .....   | 113        |
| 5.3.2            | Eslicarbazepine Acetate .....  | 114        |
| 5.3.3            | Ezogabine (Retigabine) .....   | 114        |
| 5.3.4            | Felbamate .....  | 115        |
| 5.3.5            | Gabapentin .....   | 116        |
| 5.3.6            | Lacosamide .....   | 116        |
| 5.3.7            | Lamotrigine .....  | 116        |
| 5.3.8            | Levetiracetam .....  | 118        |
| 5.3.9            | Oxcarbazepine .....  | 118        |
| 5.3.10           | Perampanel .....   | 119        |
| 5.3.11           | Pregabalin .....   | 119        |
| 5.3.12           | Rufinamide .....   | 120        |
| 5.3.13           | Stiripentol .....  | 120        |
| 5.3.14           | Tiagabine .....  | 121        |
| 5.3.15           | Topiramate .....   | 122        |
| 5.3.16           | Vigabatrin .....   | 122        |
| 5.3.17           | Zonisamide .....   | 122        |
| 5.4              | Conclusions .....  | 123        |
|                  | References .....   | 123        |
| <b>CHAPTER 6</b> | <b>Therapeutic Drug Monitoring of Antiretrovirals .....</b>                                  | <b>135</b> |
|                  | <i>Mark A. Marzinke</i>  |            |
| 6.1              | Introduction .....   | 135        |
| 6.2              | Rationale for Therapeutic Drug Monitoring<br>of Antiretroviral Agents .....                  | 137        |
| 6.3              | Antiretroviral Drug Classes .....  | 137        |
| 6.3.1            | Nucleoside/Nucleotide Reverse Transcriptase<br>Inhibitors .....                              | 137        |
| 6.3.2            | Non-Nucleoside Reverse Transcriptase Inhibitors .....  | 140        |
| 6.3.3            | Integrase Strand Transfer Inhibitors .....   | 141        |
| 6.3.4            | Protease Inhibitors .....  | 143        |
| 6.3.5            | Other Antiretroviral Classes .....   | 147        |
| 6.4              | Analytical Methodologies .....   | 148        |
| 6.5              | Clinical Trials .....  | 149        |
| 6.6              | Challenges and Limitations of Therapeutic Drug<br>Monitoring for Antiretroviral Agents ..... | 152        |
| 6.6.1            | Recommendations .....  | 152        |
| 6.7              | Conclusions .....  | 153        |
|                  | References .....   | 154        |
| <b>CHAPTER 7</b> | <b>Therapeutic Drug Monitoring in Infants and Children .....</b>                             | <b>165</b> |
|                  | <i>Uttam Garg and Clinton Frazee</i>   |            |
| 7.1              | Introduction .....   | 165        |
| 7.2              | Basic Concepts of TDM as It Relates to Infants<br>and Children .....                         | 166        |
| 7.2.1            | Absorption .....   | 166        |
| 7.2.2            | Distribution .....   | 166        |

|       |   |     |
|-------|---|-----|
| 7.2.3 | Metabolism .....                                      | 167 |
| 7.2.4 | Excretion .....                                       | 168 |
| 7.3   | Pharmacokinetic Calculations .....                    | 168 |
| 7.4   | Sample Collection, Analysis, and Interpretation ..... | 171 |
| 7.5   | Specific Drug Classes .....                           | 173 |
| 7.5.1 | Antibiotics .....                                     | 173 |
| 7.5.2 | Anticonvulsants .....                                 | 176 |
| 7.5.3 | Immunosuppressive Drugs .....                         | 177 |
| 7.5.4 | Antidepressants .....                                 | 178 |
| 7.5.5 | Cardiovascular Drugs .....                            | 178 |
| 7.5.6 | Bronchodilators .....                                 | 179 |
| 7.5.7 | Antineoplastic Drugs .....                            | 180 |
| 7.6   | Conclusions .....                                     | 181 |
|       | References .....                                      | 181 |

**CHAPTER 8 Therapeutic Drug Monitoring in Pregnancy** ..... 185  
*Sarah C. Campbell, Laura M. Salisbury, Jessica K. Roberts,  
 Manijeh Kamyar, Jeunesse Fredrickson, Maged M. Costantine  
 and Catherine M.T. Sherwin*

|       |  |     |
|-------|--|-----|
| 8.1   | Introduction .....   | 185 |
| 8.2   | TDM in Pregnancy .....   | 186 |
| 8.3   | What Drugs Warrant TDM? .....  | 186 |
| 8.4   | Steps Involved in the TDM Process .....  | 187 |
| 8.4.1 | Decision to Request a Drug Concentration .....   | 188 |
| 8.4.2 | Collection of the Sample .....   | 188 |
| 8.4.3 | Laboratory Measurement of Drug Concentrations<br>in Specimens .....                                      | 190 |
| 8.4.4 | Communication of Lab Result .....  | 191 |
| 8.4.5 | Clinical Interpretation of Drug Levels .....   | 191 |
| 8.4.6 | Implementation and Therapeutic Management .....  | 192 |
| 8.5   | Pregnancy-Induced Physiologic, Pharmacokinetic, and<br>Pharmacodynamic Changes in Drug Disposition ..... | 192 |
| 8.5.1 | Pregnancy-Induced Physiologic Changes .....  | 193 |
| 8.5.2 | Pregnancy-Induced Changes in Drug Metabolism .....   | 195 |
| 8.6   | Drugs Used in Pregnancy With Recommended TDM .....   | 196 |
| 8.6.1 | Antiarrhythmics .....  | 197 |
| 8.6.2 | Antibiotics .....  | 198 |
| 8.6.3 | Anticoagulants .....   | 198 |
| 8.6.4 | Antiepileptics .....   | 198 |
| 8.6.5 | Antidepressants/Antimanics/Antipsychotics .....  | 201 |
| 8.6.6 | Antiretrovirals .....  | 201 |
| 8.6.7 | Bronchodilators .....  | 202 |
| 8.6.8 | Immune Modulators .....  | 203 |
| 8.7   | Limitations of TDM in Pregnancy .....  | 203 |
| 8.8   | Conclusions .....  | 206 |
|       | References .....   | 206 |

|                   |   |     |
|-------------------|---|-----|
| <b>CHAPTER 9</b>  | <b>Therapeutic Drug Monitoring in Older People</b> .....  | 213 |
|                   | <i>Andrew J. McLachlan</i>  |     |
| 9.1               | Introduction.....   | 213 |
| 9.2               | Clinical Pharmacology of Medicines in Older People:<br>Implications for TDM .....   | 214 |
| 9.2.1             | Age-Related Changes in Pharmacokinetics .....   | 215 |
| 9.2.2             | Age-Related Changes in Pharmacodynamics .....   | 217 |
| 9.3               | Which Drugs and When Should TDM Be Used in Older<br>People?.....  | 218 |
| 9.4               | Studies Investigating TDM in Older People.....  | 220 |
| 9.5               | Pharmacodynamic Monitoring to Guide Dosing in Older<br>People .....   | 223 |
| 9.6               | Cost-Effectiveness of TDM in Older People .....   | 223 |
| 9.7               | Big Data and Best Evidence to Support TDM<br>in Older People.....   | 224 |
| 9.8               | Conclusions.....  | 225 |
|                   | Acknowledgments .....   | 225 |
|                   | References .....  | 225 |
| <br>              |   |     |
| <b>CHAPTER 10</b> | <b>Therapeutic Drug Monitoring in Obese Patients</b> .....  | 231 |
|                   | <i>Ventzislava Hristova and William Clarke</i>  |     |
| 10.1              | Introduction .....  | 231 |
| 10.2              | PK in Obesity .....   | 234 |
| 10.2.1            | Absorption .....  | 234 |
| 10.2.2            | Distribution.....   | 234 |
| 10.2.3            | Clearance .....   | 235 |
| 10.2.4            | Metabolism.....   | 235 |
| 10.2.5            | Renal Elimination.....  | 236 |
| 10.3              | Chemotherapy in Obese Patients .....  | 237 |
| 10.4              | Antimicrobial Treatment in Obese Patients.....  | 239 |
| 10.5              | PK After Bariatric Surgery .....  | 240 |
| 10.6              | Conclusions .....   | 242 |
|                   | References .....  | 242 |
| <br>              |   |     |
| <b>CHAPTER 11</b> | <b>Special Issues in Therapeutic Drug Monitoring<br/>in Patients With Uremia, Liver Disease,<br/>and in Critically Ill Patients</b> ..... | 245 |
|                   | <i>Kamisha L. Johnson-Davis and Amitava Dasgupta</i>  |     |
| 11.1              | Introduction .....  | 245 |
| 11.2              | Monitoring Free Drug Concentrations in Patients With<br>Uremia, Liver Disease, and in Critically Ill Patients .....                       | 246 |
| 11.3              | Altered Drug Disposition in Patients With Kidney<br>Disease .....   | 247 |
| 11.3.1            | Altered Clearance of Renally Cleared<br>Drugs in Patients With Kidney Disease .....   | 248 |
| 11.3.2            | Altered Clearance of Nonrenally Cleared<br>Drugs in Patients With Kidney Disease .....  | 249 |

|        |  |     |
|--------|--|-----|
| 11.4   | Altered Drug Disposition in Hepatic Disease .....                | 250 |
| 11.5   | Altered Drug Disposition in Critically Ill Patients .....        | 252 |
| 11.6   | Application of TDM in Critically Ill Patients .....              | 255 |
| 11.6.1 | TDM of Antimicrobial Drugs in Critically Ill Patients .....      | 255 |
| 11.6.2 | TDM of Digoxin in Critically Ill Patients .....                  | 256 |
| 11.6.3 | TDM of Sedatives and Analgesics in Critically Ill Patients ..... | 257 |
| 11.7   | Conclusions .....  | 257 |
|        | References .....   | 257 |

**CHAPTER 12** Issues of Pharmacogenomics in Monitoring Warfarin Therapy..... 261  
*Jennifer Martin and Andrew Somogyi*

|        |  |     |
|--------|--|-----|
| 12.1   | Introduction .....   | 261 |
| 12.2   | Potential for Pharmacogenomics of Warfarin.....                          | 262 |
| 12.3   | Pharmacology .....   | 263 |
| 12.3.1 | CYP2C9 Status .....  | 263 |
| 12.3.2 | VKORC Status.....  | 264 |
| 12.3.3 | Other Genetic Mutations .....  | 265 |
| 12.3.4 | Nongenetic Factors Affecting Warfarin Dosing.....                        | 266 |
| 12.3.5 | Vitamin K .....  | 268 |
| 12.3.6 | Diet.....  | 268 |
| 12.3.7 | Age .....  | 268 |
| 12.3.8 | Gender .....   | 269 |
| 12.3.9 | Anthropometric Variables .....   | 269 |
| 12.4   | Clinical Relevance.....  | 270 |
| 12.5   | Cost-Effectiveness of Pharmacogenomics Testing in Warfarin Therapy ..... | 272 |
| 12.6   | New Medications to Replace Warfarin.....                                 | 273 |
| 12.7   | Conclusions .....  | 274 |
|        | References .....   | 275 |

**CHAPTER 13** Alternative Sampling Strategies for Therapeutic Drug Monitoring .....

|        |   |     |
|--------|---|-----|
| 13.1   | Introduction .....  | 279 |
| 13.2   | The Ideal Alternative Matrix for Therapeutic Drug Monitoring .....    | 280 |
| 13.3   | The Correlation Between Alternative Matrix and Systemic Levels .....  | 282 |
| 13.4   | Alternative Specimen: Dried Blood Spots .....                         | 284 |
| 13.4.1 | Applications of Dried Blood Spots in Therapeutic Drug Monitoring..... | 290 |
| 13.5   | Alternatives to Classical Dried Blood Spots.....                      | 296 |
| 13.5.1 | Volumetric Dried Blood Spots .....                                    | 296 |
| 13.5.2 | Dried Plasma Spots.....   | 297 |
| 13.5.3 | Other Dried Matrix Spots .....  | 297 |

|                   |  |            |
|-------------------|--|------------|
| 13.6              | Paper Spray Ionization for the Analysis of Dried Blood Spots .....   | 298        |
| 13.7              | Alternative Specimen: Oral Fluid .....   | 299        |
| 13.7.1            | Applications of Oral Fluid for Therapeutic Drug Monitoring .....   | 302        |
| 13.8              | Alternative Specimen: Tears.....   | 307        |
| 13.8.1            | Application of Tears for Therapeutic Drug Monitoring .....   | 308        |
| 13.9              | Alternative Specimen: Interstitial Fluid .....   | 310        |
| 13.9.1            | Application of Interstitial Fluid for Therapeutic Drug Monitoring.....   | 311        |
| 13.10             | Alternative Specimen: Hair .....   | 312        |
| 13.10.1           | Application of Hair Specimens for Therapeutic Drug Monitoring .....  | 314        |
| 13.11             | Alternative Specimen: Exhaled Breath .....   | 316        |
| 13.11.1           | Application of Exhaled Breath for Therapeutic Drug Monitoring .....  | 317        |
| 13.12             | Alternative Specimen: Sweat.....   | 318        |
| 13.12.1           | Application of Sweat for Therapeutic Drug Monitoring .....   | 319        |
| 13.13             | Alternative Specimen: Nasal Mucus .....  | 319        |
| 13.14             | Toward Routine Implementation .....  | 319        |
| 13.15             | Conclusions .....  | 322        |
|                   | Acknowledgment .....   | 322        |
|                   | References .....   | 323        |
| <b>CHAPTER 14</b> | <b>Integrating Therapeutic Drug Monitoring in the Health Care Environment: Therapeutic Drug Monitoring and Pharmacists .....</b> | <b>337</b> |
|                   | <i>William Clarke</i>  |            |
| 14.1              | Introduction .....   | 337        |
| 14.2              | Team-Based Care in the Modern Health Care Environment .....  | 337        |
| 14.3              | Hypertension .....   | 338        |
| 14.4              | Diabetes and Hypertension .....  | 338        |
| 14.5              | Cardiovascular Diseases.....   | 339        |
| 14.6              | Pharmacists and Cost-Effective Care.....   | 339        |
| 14.7              | Impact of Health Care Information Technology on TDM .....  | 340        |
| 14.8              | Practical Examples of Integrating Pharmacy for TDM and Patient Care .....  | 341        |
| 14.8.1            | Anticoagulation .....  | 342        |
| 14.9              | Epilepsy .....   | 344        |
| 14.9.1            | Antiinfective Management.....  | 346        |
| 14.10             | Conclusions .....  | 349        |
|                   | References .....   | 349        |
|                   | <b>INDEX .....</b>   | <b>351</b> |